文献速递胸部肿瘤

中国肺腺癌人群中新发现NRG1、EGFR和MET融合

Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
PubMed 文献 · J Thorac Oncol · 2019-08-02

NRG1融合占全部肺腺癌0.36%(6/1681),包括4例CD74-NRG1、1例RBPMS-NRG1和1例新ITGB1-NRG1;另检出1例EGFR-SHC1和1例CD47-MET融合。NRG1、EGFR和MET融合在未选择肺腺癌中占0.48%。

要点

  • 中国肺腺癌中NRG1融合占0.36%,为常见驱动阴性者中最常见融合。
  • 新融合包括CD74-NRG1、RBPMS-NRG1、ITGB1-NRG1、EGFR-SHC1和CD47-MET。
  • RNA-based NGS可用于常见驱动阴性肺腺癌的可靶向融合筛查。

核心结论

  • NRG1、EGFR和MET融合在未选择中国肺腺癌中检出率为0.48%。
  • NRG1融合是常见驱动阴性中国肺腺癌中最常见的融合。

研究设计与样本

  • 连续收集手术切除的肺腺癌1681例,先用富集策略检测EGFR、KRAS、HER2、BRAF、MET、ALK、RET、ROS1和FGFR等九种常见驱动突变及融合。

主要发现

  • NRG1融合占全部肺腺癌0.36%(6/1681),包括4例CD74-NRG1、1例RBPMS-NRG1和1例新ITGB1-NRG1。
  • 另检出1例EGFR-SHC1融合和1例CD47-MET融合,均为框内融合且保留相应激酶功能域。
  • 本队列未检出NTRK、KRAS、BRAF或HER2融合。
  • 新融合病例中最常见病理亚型为浸润性黏液腺癌(3/8)和腺泡为主型腺癌(3/8)。

临床怎么用

  • 对常见驱动阴性的肺腺癌,可考虑RNA-based NGS检测NRG1、EGFR、MET等可靶向融合。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Multiple oncogene fusions beyond ALK receptor tyrosine kinase (ALK), RET, and ROS1 fusion has been described in lung cancer, especially in lung adenocarcinomas without common oncogenic mutations. Molecular inhibitors have been developed and proved effective for patients whose tumors harbor these novel alterations. METHODS: A consecutive series of surgically resected lung adenocarcinomas were collected and profiled using an enrichment strategy to detect nine common oncogenic driver mutations and fusions concerning EGFR, KRAS, HER2, BRAF, MET, ALK, RET, ROS1, and FGFR. Driver-negative cases were further analyzed by a comprehensive RNA-based next-generation sequencing (NGS) fusion assay for novel fusions. RESULTS: In total, we profiled 1681 lung adenocarcinomas, among which 255 cases were common driver-negative. One hundred seventy-seven cases had sufficient tissue for NGS fusions screening, which identified eight novel fusions. NRG1 fusions occurred in 0.36% of all lung adenocarcinoma cases (6 of 1681 cases), including 4 CD74-NRG1-positive cases, 1 RBPMS-NRG1-positive case, and 1 novel ITGB1-NRG1-positive case. Furthermore, another 2 novel fusions were also detected, including 1 EGFR-SHC1 fusion and 1 CD47-MET fusion, both of which were in-frame and retained the functional domain of the corresponding kinases. No fusion event was detected for NTRK, KRAS, BRAF or HER2 genes in this cohort. Detailed clinicopathologic data showed that invasive mucous adenocarcinoma (three of eight cases) and acinar-predominant adenocarcinoma (three of eight cases) were the most prevalent pathologic subtypes among novel fusions. CONCLUSIONS: Fusions affecting NRG1, EGFR, and MET were detected in 0.48% of unselected lung adenocarcinomas, and NRG1 fusions ranked the most prevalent fusions in common driver-negative lung adenocarcinomas from Chinese population. RNA-based NGS fusion assay was an optional method for screening actionable fusions in common driver-negative cases.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Pan Y, Zhang Y, Ye T, et al. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population. J Thorac Oncol. 2019. PMID: 31382039. doi:10.1016/j.jtho.2019.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。